All News

Samsung Bioepis Presents Real-World Switching Data for Renflexis

October 26, 2020

Tony Hagen

Article

A retrospective analysis of data from the US Veterans Affairs Healthcare System database provides positive switching data for infliximab products.

Europeans Devise Checklist for Promoting Biosimilar Use

October 24, 2020

Deana Ferreri, PhD

Article

European investigators have derived a set of core principals for developing higher utilization of biosimilars.

Biocon Reports Biosimilars Revenue Growth

October 23, 2020

Tony Hagen

Article

Biocon had a busy quarter, which included the launch of a long-acting insulin glargine product (Semglee) in partnership with Mylan.

The Top 5 Biosimilar Articles for the Week of October 19

October 23, 2020

Video

Here are the top 5 biosimilar articles for the week of October 19, 2020.

Need for Biosimilar Cooperation Among Hospitals, Infusion Centers, and Payers Is Identified

October 22, 2020

Skylar Jeremias

Article

Overcoming biosimilar uptake barriers will take collaboration and policy change by hospitals, infusion clinics, and health plans, presenters said at the Academy of Managed Care Pharmacy Nexus 2020 Virtual conference.

Biogen, Samsung Report Third-Quarter Biosimilar Results

October 21, 2020

Tony Hagen

Article

Earnings fell overall for Biogen, although biosimilar revenues continued an upward climb.

Henlius Inks Global Bevacizumab Biosimilar Distribution Deal

October 21, 2020

Tony Hagen

Article

Shanghai Henlius Biotech will share development and distribution of its bevacizumab biosimilar candidate HLX04 with Zhuhai Essex and Essex Bio-Investment.

NeuClone's Ustekinimab Candidate Shines in Phase 1 Trial

October 20, 2020

Tony Hagen

Article

Demonstrated biosimilarity across clinical parameters puts this drug among NeuClone's leading product candidates.

CT-P10 and Reference Rituximab Evaluated in Primary Sjögren Syndrome

October 20, 2020

Deana Ferreri, PhD

Article

Investigators note similar efficacy and safety profiles in real-life study of reference and biosimilar forms of rituximab.

Avalere: Step Therapy May Exacerbate Patient, Payer Costs

October 19, 2020

Tony Hagen

Article

An Avalere analysis suggests costs are more moderate and lower under a no–step therapy scenario for patients with Crohn disease.

x